Clinical trial NCT05094401: Use of an Investigational Digital Therapeutic in Patients With Type 2 Diabetes
Official title: Long-term Effectiveness and Medication Changes After Use of an Investigational Digital Therapeutic in Patients With Type 2 Diabetes Cared for in a Community Based, Clinically Integrated Network
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Type2 Diabetes
Lead sponsor: Better Therapeutics
Sponsor class: INDUSTRY
Collaborators: name: Catalyst Health Network
First posted: 2021-10-26
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Open-Label, Pragmatic
Primary purpose: TREATMENT

Brief summary: BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control (i.e., levels of blood sugar). The BT-001 software delivers a type of behavioral therapy to patients via a mobile application that targets behaviors related to achieving glycemic control. The effectiveness of BT-001 will be measured by its ability to help patients reduce Hemoglobin A1c, or HbA1c (a marker in the blood that measures blood sugar) in patients with type 2 diabetes.

Detailed description: The study will utilize an open-label, pragmatic design to confirm and characterize the safety and efficacy of BT-001 used in addition to standard of care (SOC) in patients with type 2 diabetes. The screening period will consist of review of Electronic Health Record (EHR) for participants that meet inclusion criteria and telephonic outreach.

Once confirmed consented, patients will then be given access to BT-001 for 90 days with an opportunity to continue using the product for an additional 275 days.

Participants will continue their standard of care with their provider in addition to using BT-001.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of Type2 Diabetes
* Possess a smart phone (iPhone or Android only) capable of running the smart phone application (App) used in the study;
* HbA1c level ≥7% and \<11%, as determined by the HbA1c measured within the previous 12 months;
* Willing to use a glucometer for self-monitoring blood glucose while using the study App;
* Capable of giving informed consent in English, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion Criteria:

* Unable to understand, consent to, or comply with the study protocol for any reason, including the inability to read or comprehend English. The behavioral intervention mechanisms, including educational materials and digital tools, are only available in English at this time;
* Currently taking prandial (mealtime) insulin;
* Currently experiencing heart failure of New York Heart Association Class IV;
* Currently experiencing stage 4 or 5 chronic kidney disease;
* Currently on kidney dialysis (hemo or peritoneal);
* Currently on the list for an organ transplant or previously received a transplant of any organ;
* Currently receiving treatment for cancer;
* For women only: pregnant or lactating or having the intention of becoming pregnant during the time frame of the study;
* Presumed or confirmed COVID-19 diagnosis within 90 days prior to study enrollment

Primary outcomes:
measure: Mean change in HbA1c
timeFrame: Baseline and Day 365
Secondary outcomes:
measure: Change in Medications
timeFrame: Baseline and Day 365
Other outcomes:
Locations:
city: Plano
country: United States
facility: Catalyst Health Network
state: Texas
Study officials:
References: